CURRICULUM VITAE

Name **AGOSTINI** Massimiliano
Date of birth 20 January 1972
Address Dept. Experimental Medicine
University of Rome "Tor Vergata"
via Montpellier, 1, 00133 Roma, Italy
Phone Office F485 +39 (06) 7259 6473
Phone Lab F484 +39 (06) 7259 6687
Email m.agostini@med.uniroma2.it
Twitter @agostini_massi

Associate Professor (SC 05/E2, SSD BIO/11 Biologia Molecolare)

ORCID identifier 0000-0003-3124-2072
Public record http://orcid.org/0000-0003-3124-2072
Scopus Author ID: 7005322176
Researcher ID: G-9579-2014 http://www.researcherid.com/rid/G-9579-2014

SCIENTIFIC PROFILE

Massimliano Agostini is Associate Professor in Molecular Biology at the University of Rome "Tor Vergata". He obtained his PhD in Clinical and Experimental Pharmacology (Perugia, Italy), working on the pharmacological regulation of the immune response. In 2005, he became a Research Assistant at University of Perugia (Italy). In 2007-2014, he worked at the MRC Toxicology Unit, (UK), as PostDoc and then as Senior Investigator. In 2014 worked at TW Mak's laboratory as visiting scientist (Canada). From 2014 to 2019 Visiting Scientist, MRC Toxicology Unit, Cambridge University, UK.

MA started working on the p53 family (p53, p73 and p63), characterizing isoform-selective knockout mice generated in the laboratory. MA has contributed to understanding the role of p53 family in several aspects of both physiology and pathology, including development and cancer biology. In the last 5 years, MA has investigated the role of the transcription factor ZNF750 (transcriptionally regulated by p63) in tumorogenesis by combing *in vitro* and *in vivo* models combined with system biology (transcriptomics, proteomics and metabolomics). In particular:

i) We reported a potential clinical relevance of ZNF750 in breast cancer as prognostic marker.

ii) High expression of ELOVL4 stratifies a defined cluster subsets of neuroblastoma patients with good prognosis.

EDUCATION

1997 **Degree in** Chemical and Pharmaceutical Technology
1998 Pharmacist license, state of Italy
2006 **PhD Studies** in Clinical and Experimental Pharmacology: Dept. Clinical and Experimental Medicine, Section of Pharmacology, University of Perugia, Italy.

CAREER HISTORY

1997-1999: Visiting Fellow Section of Pharmacology, School of Medicine, University of Perugia, Italy
1999-2001: Fellowship Section of Pharmacology, School of Medicine, University of Perugia, Italy
2005-2006 Research Assistant Section of Pharmacology, School of Medicine, University of Perugia, Italy
2006-2007 Research Assistant Section of Pharmacology, School of Medicine, University of Perugia, Italy
2007-2011 Career Development Fellow, MRC Toxicology Unit
2014-2014 Visiting Scientist, The Campbell Family Institute for Breast Cancer Research, Toronto, Canada
2011-2014 Senior Investigator, MRC Toxicology Unit
2014-2019 Visiting Scientist, MRC Toxicology Unit, Cambridge University, UK.

TEACHING ACTIVITIES

2015-Present II level Master, Personalized Nutrition: Molecular and Genetic bases, 1CFU
2016-Present I level Master, Nutrition and Cosmesis, 2CFU
2016-Present International Medical School (Molecular Biology 3CFU)
2017-Present Specialization School of Infection Disease (Molecular Biology 1CFU)
2019-Present Specialization School of Microbiology and Virology (Molecular Biology 1CFU)
2020-Present Course of Pharmacy (Biochemistry 6CFU)
2022-Present International Medical School (Biochemistry 1CFU)
2023-Present Scienze della nutrizione umana (Nutrition, inflammation and cancer 2CFU**)**

OTHER

2018-Present Scientific Division Torvergata Oncoscience Research (TOR), University of Rome Tor Vergata
2019-Present Scientific advisory commitee Center for Comparative Medicine, Alternative Techniques and Aquaculture
2019-Present Componente Consiglio di Scuola di Specializzazione in Endocrinologia
2019-Present Componente Consiglio di Scuola di Specializzazione in Malattie Infettive

EDITORIAL EXPERIENCE

2014-2019 Editorial board of *Molecular & Cellular Oncology*
2011-2023 Receiving Editor *Cell Death & Disease*
2011-Present Editorial board as Review Editor of Frontiers in Oncology's speciality section *Frontiers in Cancer Molecular Targets and Therapeutics*
2022-Present Editorial Board of *Cancers*
2023 Deputy Editor *Cell Death & Disease*

Ad hoc Referee:
Cell Death & Disease, Cell Death and Differentiation, Frontiers in Cancer, Molecular and Cellular Oncology, Molecular Neurobiology, Oncogene, Oncotarget, Cell Cycle, FEBS Journal, Scientific Reports, Journal of Cellular Biochemestry, Molecular Oncology, FASEB Journal, Journal of Human Genetics, Biology Direct, Discovery Oncology

PUBLICATION

Scientific Papers	74 (First Author: 17; Corresponding Author: 12)	
Citations	6251 (Scholar)	3448 (ISI) 4579 (Scopus)
h-Index	43 (Scholar)	36 (ISI) 38 (Scopus)

PUBLICATION LIST (2017-2022) (Impact Factor year of the publication)

1. **Agostini M**, Niklison-Chirou MV, Annicchiarico-Petruzzelli M, Grelli S, Di Daniele N, Pestlikis I, Knight RA, Melino G and Rufini A. p73 regulates primary cortical neurons metabolism: a global metabolic profile *Mol Neurobiol.* 2018 Apr;55(4):3237-3250. [***IF 5.39***]

2. Pisanu ME, Noto A, De Vitis C, Morrone S, Scognamiglio G, Botti G, Venuta F, Diso D, Jakopin Z, Padula F, Ricci A, Mariotta S, Giovagnoli MR, Giarnieri E, Amelio I, **Agostini M**, Melino G, Ciliberto G, Mancini R. Blockade of Stearoyl-CoA-desaturase 1 activity reverts resistance to cisplatin in lung cancer stem cells. *Cancer Lett*. 2017 Oct 10; 406:93-104. [***IF 6.37***]

3. **Agostini M***, Melino G, Bernassola F.The p53 Family in Brain Disease *Antioxid Redox Signal*. 2018 Jul 1;29(1):1-14 (*) Corresponding Author [***IF 6.33***]

4. Cassandri M, Smirnov A, Novelli F, Pitolli C, **Agostini M**, Malewicz M, Melino G and Raschellà G. Zinc-finger proteins in health and disease *Cell Death Discov.* 2017 Nov 13;3:17071.

5. Pieraccioli M, Nicolai S, Pitolli C, **Agostini M**, Antonov A, Malewicz M, Knight RA, Raschellà G, and Melino G. ZNF281 inhibits neuronal differentiation and is a prognostic marker for neuroblastoma *Proc Natl Acad Sci U S A* 2018;115(28):7356-7361 [***IF 9.55***]

6. Rotblat B, **Agostini M**, Niklison-Chirou MV, Amelio I, Willis AE and Melino G Sustained protein synthesis and reduced eEF2K levels in TAp73-\- mice brain: a possible compensatory mechanism *Cell Cycle* 2018;17(23):2637-2643. [***IF 3.25***]

7. **Agostini M**, Ganini G, Candi E and Melino G The role of non-coding RNAs in epithelial cancer *Cell Death Discov* 6, 13 (2020). (*) Corresponding Author [***IF 4.11***]

8. Cassandri M, Butera A, Amelio I, Lena AM, Montanaro M, Mauriello A, Anemona L, Candi E, Knight RA, **Agostini M** and Melino G. ZNF750 represses breast cancer invasion via epigenetic control of prometastatic genes *Oncogene* 39, 4331–4343 (2020) (*) Corresponding Author [***IF 7.97***]

9. Amelio I, Panatta P, Niklison-Chirou MV, Steinert J, **Agostini M**, Morone N, Knight RA, Melino G The p73 C-terminus directs hippocampal development *Proc Natl Acad Sci U S A* 2020 117 (27) 15694-15701 [***IF 9.41***]

10. Niklison-Chirou MV, **Agostini M***, Amelio I and Melino G Regulation of Adult Neurogenesis in Mammalian Brain *Int. J. Mol. Sci.* 2020, *21*(14), 4869; *Co-First Author [***IF 4.55***]

11.Butera A, Cassandri M, Rugolo F, **Agostini M*** and Melino G The ZNF750-RAC1 axis as potential prognostic factor for breast cancer *Cell Death Discov* 2020; 6(1):135 (*) Corresponding Author [***IF 4.1***]

12.Velletri T, Huang Y, Wang Y, Li Q, Hu M, Xie N, Yang Q, Chen X, Chen Q, Shou P, Gan Y, Candi E, Annicchiarico-Petruzzelli M, **Agostini M**, Melino G, Shi Y, Yang H and Wang Y Loss of p53 in mesenchymal stem cells promotes alteration of bone remodelling through negative regulation of osteoprotegerin *Cell Death Differ* 2021;28(1):156-169. [***IF 15.82***]

13.Rugolo F, Bazan NG, Calandria J, Jun B, Raschellà G, Melino G, and **Agostini M** The expression of ELOVL4, repressed by MYCN, defines neuroblastoma patients with good outcome *Oncogene* 2021;40(38):5741-5751 [***IF 9.86***]

14.Lena AM, Foffi E, **Agostini M**, Mancini M, Annicchiarico-Petruzzelli M, Aberdam D, Velletri T, Shi Y, Melino G, Wang Y and Candi E TAp63 regulates bone remodeling by modulating the expression of TNFRSF11B/Osteoprotegerin *Cell Cycle* 2021;20(22):2428-244 [***IF 4.53***]

15.**Agostini M*,** Melino G, Habeb B Calandria JM and Bazan NG Targeting lipid metabolism in cancer: neuroblastoma *Cancer Metastasis Rev* 2022; 41(2): 255–260 (*) Corresponding Author [*IF* ***9.237***]

16.**Agostini M**, Mancini M and Candi E Long non-coding RNAs affecting cell metabolism in cancer *Biol Direct.* 2022;17(1):26 [***IF 4.78***]